Citigroup
LUMO

Citigroup’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Citigroup’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-444
Closed -$19K – 7895
2018
Q2 		$19K Sell
444
-1,123
-72% -$51.4K ﹤0.01% 6952
2018
Q1 		$102K Sell
1,567
-2,955
-65% -$209K ﹤0.01% 5601
2017
Q4 		$330K Sell
4,522
-1,400
-24% -$116K ﹤0.01% 4543
2017
Q3 		$543K Buy
5,922
+3,878
+190% +$297K ﹤0.01% 4036
2017
Q2 		$135K Buy
2,044
+588
+40% +$72.8K ﹤0.01% 5104
2017
Q1 		$316K Sell
1,456
-4,511
-76% -$644K ﹤0.01% 4257
2016
Q4 		$552K Buy
5,967
+2,489
+72% +$280K ﹤0.01% 4273
2016
Q3 		$470K Sell
3,478
-1,244
-26% -$124K ﹤0.01% 3944
2016
Q2 		$479K Buy
4,722
+1,733
+58% +$215K ﹤0.01% 3708
2016
Q1 		$490K Sell
2,989
-989
-25% -$200K ﹤0.01% 4131
2015
Q4 		$1.3M Buy
3,978
+489
+14% +$159K ﹤0.01% 2848
2015
Q3 		$1.13M Sell
3,489
-22
-0.6% -$9.66K ﹤0.01% 2967
2015
Q2 		$1.4M Buy
3,511
+2,633
+300% +$1.12M ﹤0.01% 2868
2015
Q1 		$432K Buy
+878
New +$340K ﹤0.01% 3886

Other funds holding LUMO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup's LUMO Position: Q2 2021 in Review

Citigroup sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2021, closing a stake of 1,000 shares — an estimated $12K sold.

Citigroup first reported a position in LUMO in Q2 2013 and held it in 27 quarters. The position peaked at $958K in Q1 2016. 40 funds tracked by Wall St. Rank hold LUMO as of Q2 2021.

  • Citigroup reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Citigroup sold 1,000 Lumos Pharma, Inc. Common Stock shares in Q2 2021, an estimated $12K.
  • Citigroup first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 27 quarters.
  • Citigroup's Lumos Pharma, Inc. Common Stock position peaked at $958K in Q1 2016.
  • 40 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2021.

Based on Citigroup's 13F filing for Q2 2021, filed 10 Aug 2021.